Goldman Sachs
OBIO icon

Goldman Sachs’s Orchestra BioMed OBIO Stock Holding History

Goldman Sachs’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$775K Buy
179,606
+24,364
+16% +$99.6K ﹤0.01% 5412
2026
Q1 		$660K Buy
155,242
+21,169
+16% +$90.1K ﹤0.01% 5401
2025
Q4 		$556K Buy
134,073
+110,443
+467% +$446K ﹤0.01% 5525
2025
Q3 		$58.6K Sell
23,630
-73,211
-76% -$202K ﹤0.01% 6153
2025
Q2 		$260K Buy
96,841
+48,112
+99% +$140K ﹤0.01% 5523
2025
Q1 		$209K Sell
48,729
-13,408
-22% -$66.7K ﹤0.01% 5622
2024
Q4 		$249K Buy
62,137
+20,098
+48% +$108K ﹤0.01% 5559
2024
Q3 		$216K Buy
+42,039
New +$275K ﹤0.01% 5428
2022
Q3 		– Sell
-94,036
Closed -$937K – 6456
2022
Q2 		$937K Buy
94,036
+35,700
+61% +$355K ﹤0.01% 4665
2022
Q1 		$578K Buy
+58,336
New +$576K ﹤0.01% 5222

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Goldman Sachs's OBIO Position: Q2 2026 in Review

Goldman Sachs increased its Orchestra BioMed (OBIO) stake by 16% in Q2 2026, buying an estimated $99.6K and bringing the position to 179,606 shares worth $775K. The position accounts for ﹤0.01% of the portfolio, ranked #5412.

Goldman Sachs first reported a position in OBIO in Q1 2022 and has held it in 10 quarters since. The position peaked at $937K in Q2 2022. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Goldman Sachs held 179,606 shares of Orchestra BioMed worth $775K as of Q2 2026.
  • Goldman Sachs bought 24,364 Orchestra BioMed shares in Q2 2026, an estimated $99.6K.
  • Orchestra BioMed made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5412 holding.
  • Goldman Sachs first reported a position in Orchestra BioMed in Q1 2022 and has held it in 10 quarters since.
  • Goldman Sachs's Orchestra BioMed position peaked at $937K in Q2 2022.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.